QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-18

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the p...

Core News & Articles

GPRK: 28% | Geopark shares are trading higher after Parex Resources submitted a proposal to acquire all outstanding shares of t...

 intellia-therapeutics-stock-is-diving-again-heres-why

Intellia Therapeutics shares are tumbling in after-hours trading on Wednesday. Here's what you need to know.

 intellia-therapeutics-announces-that-fda-has-placed-a-clinical-hold-on-the-investigational-new-drug-applications-for-the-magnitude-and-magnitude-2-phase-3-clinical-trials-for-nexiguran-ziclumeran

-SEC Filing

 wells-fargo-downgrades-intellia-therapeutics-to-equal-weight-lowers-price-target-to-17

Wells Fargo analyst Yanan Zhu downgrades Intellia Therapeutics (NASDAQ:NTLA) from Overweight to Equal-Weight and lowers the ...

 jmp-securities-maintains-market-outperform-on-intellia-therapeutics-lowers-price-target-to-29

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and lowers the...

 barclays-maintains-overweight-on-intellia-therapeutics-lowers-price-target-to-24

Barclays analyst Gena Wang maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target from ...

 rbc-capital-downgrades-intellia-therapeutics-to-sector-perform-lowers-price-target-to-14

RBC Capital analyst Luca Issi downgrades Intellia Therapeutics (NASDAQ:NTLA) from Outperform to Sector Perform and lowers th...

 bernstein-downgrades-intellia-therapeutics-to-market-perform-raises-price-target-to-145

Bernstein analyst William Pickering downgrades Intellia Therapeutics (NASDAQ:NTLA) from Outperform to Market Perform and rai...

 b-of-a-securities-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-30

B of A Securities analyst Greg Harrison maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target...

 hc-wainwright--co-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the p...

 chardan-capital-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-48

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION